Prostate Cancer and Prostatic Diseases

Papers
(The TQCC of Prostate Cancer and Prostatic Diseases is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study133
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction71
Correction to: Advances in PSMA-targeted therapy for prostate cancer65
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging65
More evidence that physical activity is beneficial for prostate cancer58
Best of 2022 in prostate cancer and prostatic diseases51
The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis50
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer50
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?47
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States44
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer43
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?42
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis39
Sexual outcomes in men who have sex with men who underwent radical prostatectomy36
Germline alterations among Hispanic men with prostate cancer36
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)35
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study34
Concerns regarding prostate cancer screening guidelines in minority populations33
New BPH therapy classification: what really FITs?33
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro29
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches28
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer28
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions28
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study27
TRexit is going one step further27
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations27
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer27
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer26
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer26
LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations25
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy25
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure25
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis24
Feasibility and safety study of the Flostent™ system (RAPID-I)24
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts24
Incidence of prostate cancer in transgender women in the US: a large database analysis24
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency24
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms24
The microbiome and prostate cancer23
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids23
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer23
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database23
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions22
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants22
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT22
Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database22
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate22
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature22
Antimicrobial prophylaxis: To do or not to do? This is the question21
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients21
Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?21
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?21
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction21
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis21
The times have changed. Let the urologists change!20
The effects of glycemic index on prostate cancer progression in a xenograft mouse model20
“Targeted microwave ablation: another way to kick the can(cer) down the road?”20
Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days’ follow-up20
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision20
The evolving clinical use of prostate cancer biomarkers20
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)19
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials19
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study19
Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system18
Prognostic value of MR visibility/invisibility in men on Active Surveillance18
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate18
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!18
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy18
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics18
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases18
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry17
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis17
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells17
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis17
The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis17
Association of prostate cancer with human papillomavirus infections: a case-control study17
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK17
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey17
Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia16
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer16
Sleep disturbances are underappreciated in prostate cancer survivorship16
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies16
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan16
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification16
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy16
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT16
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer16
Correction: Estimating patient health in prostate cancer treatment counseling16
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial15
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials15
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review15
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial15
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study15
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”15
Risk calculators for the detection of prostate cancer: a systematic review15
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores15
Less is more: the “Safety Net Approach” balances precision and safety15
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy15
The obesity paradox in metastatic castration-resistant prostate cancer14
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis14
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications14
Cardiovascular risk in ADT recipients: does the type of ADT matter?14
Drivers of racial disparities in prostate cancer trial enrollment14
Characteristics of incidental prostate cancer in the United States14
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?14
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer14
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN13
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape13
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer13
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer13
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey13
Prevalence and determinants of shared decision-making for PSA testing in the United States13
The impact of race on survival in metastatic prostate cancer: a systematic literature review12
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz12
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?12
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial12
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer12
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta12
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review12
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed12
Hyperglycemia and microRNAs in prostate cancer12
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis12
Best of 2023 in Prostate Cancer and Prostatic Diseases11
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only11
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting11
The changing face of castrate resistant prostate cancer11
Biopsy strategies in the era of mpMRI: a comprehensive review11
Quality of information and appropriateness of ChatGPT outputs for urology patients11
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes11
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study11
Prostate cancer and prostatic diseases is “Your” journal10
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?10
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations10
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients10
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry10
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)10
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?10
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration10
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment10
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study10
Surveillance after Focal Therapy – a Comprehensive Review9
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis9
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer9
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis9
Best of 2024 in Prostate Cancer and Prostatic diseases9
Quality of information and appropriateness of Open AI outputs for prostate cancer9
Overcoming barriers to prostate cancer genetic testing: who, when, and how9
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT9
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer9
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer9
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis9
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer9
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH9
0.065518856048584